CSM Advisors LLC Invests $2.97 Million in Inogen, Inc $INGN

CSM Advisors LLC acquired a new position in shares of Inogen, Inc (NASDAQ:INGN) during the third quarter, HoldingsChannel reports. The firm acquired 364,100 shares of the medical technology company’s stock, valued at approximately $2,973,000.

Other institutional investors have also added to or reduced their stakes in the company. Kent Lake PR LLC boosted its stake in Inogen by 5.7% in the 2nd quarter. Kent Lake PR LLC now owns 1,061,294 shares of the medical technology company’s stock worth $7,461,000 after purchasing an additional 57,700 shares during the period. Ameriprise Financial Inc. raised its stake in shares of Inogen by 0.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 881,100 shares of the medical technology company’s stock valued at $6,194,000 after purchasing an additional 6,573 shares during the period. Armistice Capital LLC bought a new stake in shares of Inogen in the second quarter valued at about $4,668,000. Prudential Financial Inc. lifted its holdings in shares of Inogen by 7.9% in the second quarter. Prudential Financial Inc. now owns 647,188 shares of the medical technology company’s stock valued at $4,550,000 after purchasing an additional 47,267 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Inogen by 7.9% during the second quarter. Geode Capital Management LLC now owns 615,279 shares of the medical technology company’s stock worth $4,326,000 after buying an additional 44,860 shares during the period. 89.94% of the stock is owned by institutional investors.

Inogen Price Performance

Shares of INGN stock opened at $6.13 on Tuesday. The company has a fifty day moving average price of $6.13 and a two-hundred day moving average price of $7.13. Inogen, Inc has a one year low of $5.34 and a one year high of $9.13. The stock has a market cap of $166.93 million, a P/E ratio of -7.13 and a beta of 1.77.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, February 24th. The medical technology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.10. The company had revenue of $81.72 million for the quarter, compared to analyst estimates of $82.00 million. Inogen had a negative net margin of 6.52% and a negative return on equity of 11.56%. As a group, equities research analysts anticipate that Inogen, Inc will post -1.73 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $11.00.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.